kandrozid 16 mg tabletti
viatris limited - candesartan cilexetil - tabletti - 16 mg - kandesartaani
kandrozid 32 mg tabletti
viatris limited - candesartan cilexetil - tabletti - 32 mg - kandesartaani
olmesartan medoxomil/hydrochlorothiazide krka 20 mg / 12.5 mg tabletti, kalvopäällysteinen
krka, d.d., novo mesto - hydrochlorothiazide, olmesartan medoxomil - tabletti, kalvopäällysteinen - 20 mg / 12.5 mg - olmesartaanimedoksomiili ja diureetit
olmesartan medoxomil/hydrochlorothiazide krka 20 mg / 25 mg tabletti, kalvopäällysteinen
krka, d.d., novo mesto - hydrochlorothiazide, olmesartan medoxomil - tabletti, kalvopäällysteinen - 20 mg / 25 mg - olmesartaanimedoksomiili ja diureetit
clarithromycin accord 250 mg tabletti, kalvopäällysteinen
accord healthcare b.v. accord healthcare b.v. - clarithromycinum - tabletti, kalvopäällysteinen - 250 mg - klaritromysiini
clarithromycin accord 500 mg tabletti, kalvopäällysteinen
accord healthcare b.v. accord healthcare b.v. - clarithromycinum - tabletti, kalvopäällysteinen - 500 mg - klaritromysiini
takhzyro
takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedeema, perinnöllinen - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.
orladeyo
biocryst ireland limited - berotralstat dihydrochloride - angioedeema, perinnöllinen - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.
aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxysmal - immunosuppressantit - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.